{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.55","upperLimit":"7.17","value":"4.87"},{"groupId":"OG001","lowerLimit":"1.38","upperLimit":"6.83","value":"1.58"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"9"}],"units":"Participants"}],"description":"PK parameters of Total Anti-TROP2 Antibody\\_Time to maximum plasma concentration","dispersionType":"Full Range","groups":[{"description":"Final Analysis with DCO on 06May2024","id":"OG000","title":"TNBC Cohort"},{"description":"Final Analysis with DCO on 27Nov2024","id":"OG001","title":"NSCLC Cohort"}],"paramType":"MEDIAN","populationDescription":"PK analysis set: Enrolled participants who have received at least one dose of treatment and had measurable serum concentrations of Dato-DXd.","reportingStatus":"POSTED","timeFrame":"TNBC cohort: from enrollment to 13 months post last subject dose with a median of 12 months follow up. NSCLC cohort: from enrollment to 20 months post last subject dose with a median of 16.7 months follow up.","title":"Pharmacokinetic Parameter: Time to Maximum Plasma Concentration (Tmax) _Total Anti-TROP2 Antibody","type":"SECONDARY","unitOfMeasure":"Hour"}